Percy Carter Net Worth & Insider Trades

Percy Carter - CHIEF SCIENTIFIC OFFICER, Blueprint Medicines Corp

As of June 7, 2023

What is Percy Carter's Net Worth?

The current estimated net worth of Blueprint Medicines Corp's CHIEF SCIENTIFIC OFFICER, Percy Carter, is estimated to be about $1.64M . Percy Carter owns about 38,117 units of Blueprint Medicines Corp common stock. In the last 2 years at Blueprint Medicines Corp, Percy Carter has sold an estimated value of $268.89K worth.

What is Percy Carter's Past Insider Trading?

Percy Carter's largest sale order was 2,307 units , worth over $120.1K on June 7, 2023. In total, Percy Carter has made about 6 transactions over 2 years of their time at Blueprint Medicines Corp. Percy Carter usually trades in March and June, with the busiest year in 2023.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

Price per Share
Filing Date
No matching records found


Our partner InsideArbitrage provides a full suite of tools and analysis that allows you to find opportunities from the hundreds of insiders transactions filed by company insiders each week. The service includes the popular Insider Weekends articles that highlight the top 5 insider purchases and sales each week as well as detailed analysis of one company each week. The service also includes several custom screens such as the Double Dipper that includes a list of companies that are buying back their shares while their insiders are independently buying stock on the open market for their own portfolios.

What is Percy Carter's' Mailing Address?

  • Mailing address is C/o Blueprint Medicines Corporation 45 Sidney Street Cambridge MA 02139 MA

Blueprint Medicines Corp Executive Compensation

Jeffrey W. Albers 2020 $645,000 $6,344,667
Jeffrey W. Albers 2019 $590,000 $9,362,371
Jeffrey W. Albers 2018 $541,144 $9,740,799
Michael Landsittel 2020 $379,575 $2,014,974
Michael Landsittel 2019 $345,000 $1,958,720
Michael Landsittel 2018 $281,678 $1,740,610
Fouad Namouni, M.D. 2020 $186,154 $6,668,732
Fouad Namouni, M.D. 2019 - -
Fouad Namouni, M.D. 2018 - -
Kathryn Haviland 2020 $460,944 $2,363,556
Kathryn Haviland 2019 $431,830 $3,090,423
Kathryn Haviland 2018 $392,589 $2,601,762
Tracey L. McCain, Esq. 2020 $453,301 $2,346,428
Tracey L. McCain, Esq. 2019 $437,972 $2,900,568
Tracey L. McCain, Esq. 2018 $425,216 $2,647,962
No matching records found


What are Blueprint Medicines Corp's Past Insider Trades?

Blueprint Medicines Corp's most recent insider trade came on August 28, 2023 by Jeffrey Albers who sold 25,000 units worth $1.25M . In the last 8 years, insiders at Blueprint Medicines Corp have sold an estimated value of $176.92M and bought an estimated value of $17.68M worth of shares. Insider trading is most common in March, with the busiest year in 2020. The most active traders at the company are Jeffrey Albers,  Kate Haviland, CHIEF EXECUTIVE OFFICER,  and Ariel Hurley, PRINCIPAL ACCOUNTING OFFICER .

Blueprint Medicines Corp Insider Trades

Date Range: All Time
Insider Names
Price per Share
Filing Date
No matching records found